The vasculature of mouse breast tumor spheroids grown on mammary fat pad tissue in an intravital microscopy (IVM) viewing chamber was shown to derive from infiltrating angiogenic mammary vessels. The receptors tissue factor (TF), a V b 3 integrin and Tie-2 were expressed on the vascular endothelium in the periphery but not in the center of the tumor spheroids nor in the mammary tissue nor in smooth muscle tissue, whereas Tie-1 and PCAM-1 were expressed extensively in the entire tumor and in the vascular endothelium of the entire tumor nodule and in normal mammary tissue. TF is a specific target for adenoviral vector-mediated cancer immunotherapy. Subcutaneous injection of the AdfVII/IgG 1 Fc vector leads to the release into the system circulation of a fVII/ IgG 1 Fc immunoconjugate molecule that binds specifically and tightly to TF on vascular endothelial cells and tumor cells, activating a cytolytic immune response against the targeted cells. We show that a single administration of the AdfVII/IgG 1 Fc vector destroys the peripheral but not the central vasculature of a tumor spheroid, causing partial tumor regression; additional administrations prevent regeneration of the peripheral vasculature and regrowth of the tumor. These findings indicate that a critical parameter for optimizing tumor damage is the schedule for successive administrations of the AdfVII/IgG 1 Fc, which should coincide with the regeneration of the peripheral vasculature and continue until the tumor is destroyed.
Introduction
Several differences have been reported between the vasculature in normal tissues as compared to solid tumors. [1] [2] [3] [4] [5] [6] [7] [8] Endothelial cells of the normal vasculature of normal tissues do not divide and form tight junctions that prevent free diffusion of ions and molecules into the tissue. In contrast, endothelial cells of a tumor vasculature contain 15-30% dividing cells and form a leaky endothelium, allowing free diffusion of ions and small molecules into the tumor. Other differences involve expression of the receptors tissue factor, a V b 3 and Tie-2 on the vascular endothelial cells of solid tumors but not of normal tissues. [9] [10] [11] [12] [13] [14] [15] [16] The kinetics of solid tumor growth has three phases: an initial phase of slow growth, a second phase of more rapid growth and a third phase of slow growth. 7 This growth pattern was shown to fit a mathematical function 7 that was interpreted in terms of variable rates of 'birth' and 'death' of tumor cells between the interior and periphery of the tumor as growth progresses.
Here, we describe differences in expression tissue factor, a V b 3 integrin receptor and the Tie-2 receptor on vascular endothelial cells between the interior and periphery of a tumor, which could account for the phased kinetics of tumor growth. We demonstrate that tissue factor provides a target for selective destruction of the peripheral vasculature, mediated by the AdfVII/ IgG 1 Fc vector that activates a cytolytic immune attack against vascular endothelial cells expressing tissue factor.
Materials and methods

Cell lines
The N202.1 cell line, which was derived from a primary breast cancer tumor from a mouse strain, which was transgenic in the rat Her-2-Neu gene (H2N.Tg mouse), was obtained from Dr P-L Lollini (University of Bologna, Bologna, Italy). The N202 cell line used in some of our experiments had been modified by Borgstrom and colleagues 8 by transfection of a plasmid carrying a histone 2B-green fluorescent protein (H2B-GFP) transcription unit. The H2B-GFP protein in the N202 cells, which leads to binding of the GFP protein to cellular DNA, provides a tool for the quantitative evaluation by intravital microscopy of changes in the total tumor cell mass in the dorsal skin fold chamber.
Plasmids: m fVII/IgG 1 Fc and mfVII-GFP
The adenoviral vector encoding the mfVII immunoconjugate-PcDNA3-mIcon was obtained from the Garen laboratory. [17] [18] [19] [20] The amplified mfVII cDNA, which contains the leader and coding sequences without a stop codon, was cloned into the HindIII and BamHI sites of the pcDNA3.1( þ ) vector (Invitrogen, Carlsbad, CA) in-frame with a cDNA encoding the human IgG1 Fc domain. The vector DNA was amplified in HB101 competent cells (Life Technologies, Grand Island, NY) and sequenced. The active site of mfVII cDNA was mutated as described originally by Hu and Garen [17] [18] [19] [20] substituting an alanine codon for Lys-341. The mutagenesis procedure was carried out as described in the QuickChange site-directed mutagenesis manual (Stratagene, La Jolla, CA). The 5 0 primer was 5 0 -GGTAC CAAGGACGCCTGCGCGGGTGACAGCGGTGGCC CA-3 0 , and the 3 0 primer was 5 0 -TGGGCCACCGCTGT CACCCGCGCAGGCGTCCTTGGTACC-3 0 . The mfVII cDNA with the active site mutation is designated mfVIIasm. The plasmid containing mfVIIasm cDNA was transformed into HB101 competent cells, and transformed colonies were selected on 2 Â TY/carbenicillin agar. The sequence of the plasmid DNA showed a substitution of an alanine codon (GCG) for the Lys-341 codon (AAG) in the mfVIIasm DNA.
For the construction of the adenoviral vector encoding mfVII-GFP, we used polymerase chain reaction to amplify the mfVIIasm including the hinge region of hIgG Fc. The 5 0 primer was TAAGCTTAGTC TCAT CATGGTTCCACAGGCGCATGG and the 3 0 primer was G GAATTCGAAGACTGA CGGTCCCCCCAG GAGTTC. The amplified mfVII with hinge region cDNA was cloned into the HindIII and EcoRI sites of the pcDNA3.1( þ ) vector (Invitrogen) in-frame with enhanced green fluorescent protein (EGFP)-HIS tag. The template for amplification of EGFP was the vector pEGFP-N1 (Clontech, Mountain View, CA). The primers for amplification of the EGFP-His are: 5 0 -TGGAG GCGCGGAATTCATGGTGAGC AAGGGCGAGGA GCTGTTCACC-3 0 , and 5 0 -TCTCGAGTCAATGGTGA TGGTATG ATG ATGACCGGTCTTGTACAGCTCG TCCAT GCCGAGAGTGATC-3 0 .
In vitro synthesis of fVII/IgG 1 Fc protein The procedures for transfecting the fVII/IgG 1 Fc immunoconjugate cDNA into Chinese Hamster ovary (CHO) cells and isolating clones were described previously. [17] [18] [19] [20] In vivo intravital microscopy (IVM) Dorsal skin fold chambers in the mouse were prepared as described previously. 8, 21 Tumor spheroids were derived from N202-H2B-GFP and was plated at 1 Â 10 5 cells/well in 100 ml/well in a 96-well round-bottomed plates coated with 50 ml of 1% agarose. The tumor spheroids were allowed to compact for 48 h, washed in serum-free medium, and then implanted into the chambers. Fluorescence microscopy was performed using a Mikron Instrument Microscope (Mikron Instrument, San Diego, CA) equipped with an epi-illuminator and video-triggered stroboscopic illumination from a xenon arc (MV-7600; EG&G, Salem, MA) as described previously. 8, 21 Fixation, processing and in vitro photography of fixed tissue from dorsal skin fold chamber Tissue sections were mounted onto slides and allowed to dry at room temperature, and fixed in cold acetone for 2 min at À201C. The slides were then incubated in fluorescein isothiocyanate (FITC)-conjugated anti-EGFP antibody as described in the FluoReporter FITC Protein Labeling Kit (Molecular Probes, Carlsbad, CA). These samples were then incubated with phycoerythrin (PE)-conjugated antibodies to mouse CD31 (Pharmingen, San Diego, CA), the Tie-1 receptor (Santa Cruz Biotechnology, Santa Cruz, CA), the Tie-2 receptor (eBioscience) and the a V b 3 integrin receptor (Santa Cruz Biotechnology). Each antibody had been diluted at 1:100 with 1% bovine serum albumin (BSA) in phosphate-buffered sulfate (PBS) and incubated for 1 h at room temperature.
Purification of mfVII-GFP protein
The procedures for transfecting the mfVII-GFP and fVII/ IgG 1 Fc immunoconjugate cDNAs into CHO cells and isolating clones have been described previously. 
Results
Distribution of receptors on vascular endothelial cells of tumor spheroids
Tumor spheroids derived from mouse N202 breast cancer cells were implanted on normal mammary fat pad tissue in an IVM viewing chamber on the skin of nude mice, which allows monitoring in vivo the development of the tumor spheroid. The vasculature of the mammary fat pad extensively invaginates the growing tumor spheroid within 10 days after implantation (Figure 1a) . To map the distribution of TF in the tumor spheroid, the mice were injected by tail vein with a mfVII-GFP protein probe that binds tightly and specifically to TF, and the tumor spheroid was photographed using laser photomicrography that is excitatory for GFP. The tumor spheroids were removed from the viewing chamber, permeated with optical coherence tomography (OCT) medium, frozen and sectioned, and the sections were stained with PE-conjugated antibodies against the vascular endothelial cell markers a V b 3 integrin, CD31 (PCAM-1), and Tie-1 and Tie-2 receptors. Staining of a V b 3 integrin and Tie-2 receptors occurred only in the peripheral vasculature of the tumor spheroid, in contrast to the staining of CD31 and Tie-1 receptor that occurred in the central as well as the peripheral vasculature (see Table 1 ). Each vascular marker colocalized with tissue factor in the tumor spheroid (see Table 2 ), indicating that tissue factor provides an accessible and specific therapeutic target for the peripheral tumor vasculature.
The distribution of angiogenic receptors in the periphery and center of a tumor nodule derived from the MD MBA 435 human breast cancer cell line growing in nude mice As shown above in Figure 1b and Table 2 , the vasculature of the tumor spheroid in the dorsal skin fold chamber is heterogeneous, with the angiogenic receptors present at the periphery but not in the center of the tumor. In order to test if this type of heterogeneity is also found in larger tumors growing in the subcutaneous space, we harvested subcutaneous tumor nodules, which were derived from the MD MBA 435 human breast cancer cell line growing in nude mice. We used fluorescence confocal microscopy of frozen sections of the periphery (see left hand panel of Figure 1c ) and the center (see right hand panel of Figure 1c ) of the tumor nodule following exposure to a PE-conjugated antibody to the Tie-2 receptor (angiogenic) or a FITC-conjugated antibody to the Tie-1 receptor (non-angiogenic). As shown in Figure 1c , the Tie-2 receptor was detectable only at the periphery of the tumor nodule whereas the Tie-1 receptor was detectable both at the periphery as well as in the center of the tumor.
Testing of the effect of a single intravenous injection of the fVII/IgG 1 Fc immunoconjugate protein on the vessels of the N202 breast cancer spheroid in the dorsal skin fold chamber of live mice As mentioned above and published previously, [17] [18] [19] Abbreviation:GFP, green fluoroscent protein. We studied the effect of intravenous injections of the mfVII/hIgG 1 Fc protein which extended over 11 days. As shown below in Table 3 , the size of the tumor spheroid was reduced to 50% of the pretreatment value at 24 h following the intravenous injection of the mfVII/hIgG 1 Fc protein. Additional intravenous injections of the mfVII/ hIgGFc at 3 and 7 days following the initial injection did not reduce the mass of the tumor spheroid any further. We then studied the effect of the AdmfVII/hIgG 1 Fc vector when injected intratumorally. We carried four sequential intratumoral injections of an adenoviral vector which encoded the mfVII/hIgG 1 Fc protein into a breast cancer subcutaneous tumor nodule. This mouse also carried a dorsal skin fold chamber with a N202 breast cancer tumor spheroid growing on an explant of a mammary fat pad. These injections, which started 10 days following implantation of the tumor spheroid, were designed to test if the mfVII/hIgG 1 Fc protein released continuously into the blood stream from vector-infected tumor cells in the subcutaneous tumor nodule, could suppress the growth of the tumor spheroid growing at a distant site in the dorsal skin fold chamber. As shown in Figure 3 , in the mice which four sequential injections of the AdmfVII/hIgG 1 Fc into a subcutaneous tumor nodule were carried out, the growth of the tumor spheroid was completely suppressed (solid triangles and solid squares in Figure 3 ).
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Effect of mfVII/hIgG 1 Fc on vascular markers in breast cancer spheroid vessels The data presented above in Table 3 and Figure 3 suggests that the vessels of the tumor spheroid are heterogeneous, some sensitive to the mfVII/hIgG 1 Fc protein and some not. The initial exposure of the tumor vessels to the mfVII/hIgG 1 Fc protein may denude the luminal endothelial cells of all available tissue factor binding sites. In order to directly test this hypothesis, we first intravenously injected the fully functional mfVII/ hIgG 1 Fc protein followed in 24 h by an intravenous injection of the mfVII-GFP protein in nude mice. This mouse carried a dorsal skin fold chamber in which the N202 breast cancer tumor spheroid was growing on an explant of the fat pad tissue of a lactating nursing mouse. We injected another such mouse with a single intravenous injection of the mfVII-GFP protein without a preceding mfVII/hIgG 1 Fc protein injection.
One hour after the administration of the mfVII-GFP protein by tail vein, both mice were killed, the tumor tissue from the dorsal skin fold chamber harvested, permeated with OCT solution, frozen in the vapor phase of dry ice, and sectioned. We photographed the frozen sections from this tissue with a laser which was excitatory for GFP. As shown in Figure 4a , many bright spots appear in the left hand panel (binding of the mfVII-GFP) whereas only three spots appear in the right hand panel. The light background is autoflurorescence, whereas the bright spots replect binding of the mfVII-GFP. Thus, the pretreatment of the mouse with the mfVII/hIgGFc protein dramatically reduced the binding of the mfVII-GFP protein (right hand panel of Figure 4a ) to the tumor vasculature as compared to the level of mfVII-GFP binding seen in a mouse which did not receive a mfVII/ hIgG 1 Fc injection (left panel of Figure 4a ).
Frozen sections similar to those shown in Figure 4a were then stained with FITC-conjugated antibody for GFP or a PE-conjugated antibody for the Tie-1 receptor. As shown in Figure 4b , many yellow dots (as well as green and red dots) are present in the left hand panel (periphery of tumor spheroid of a mouse injected with the mfVII-GFP protein only) whereas the right hand panel (periphery of tumor spheroid of a mouse injected with the mfVII/hIgG 1 Fc first and then with the mfVII-GFP 24 h later) has red color without green or yellow dots). These results show the coincidence of the binding of the anti-GFP antibody and the PE-conjugated antibody for the Tie-1 receptor in the tissues in animals treated only with the mfVII-GFP (left hand panel of Figure 4b ). In contrast, when the fully functional mfVII/hIgG 1 Fc protein is injected intravenously 24 h before the mfVII-GFP protein injection (right hand panel of Figure 4b ), no In a similar manner, there was no staining by a secondary PE-conjugated antibody to the Tie-2 receptor, or to the a V b 3 integrin receptor in tissue previously exposed to the mfVII/hIgG 1 Fc protein. This suggests that exposure to the mfVII/hIgG 1 Fc protein strips the endothelial cells in the vasculature of the tumor spheroid of markers such as tissue factor, thereby preventing further binding of injected mfVII-GFP in mfVII/ hIgG 1 Fc-pretreated animals.
Effect the mfVII/hIgG 1 Fc adenoviral vector on subcutaneous nodules derived from the human MD MBA 435 breast cancer cell line in nude mice when the vector injections are administered: (1) into tumor, (2) into liver, (3) into muscle, and (4) into the subcutaneous space We then tested the effect of intratumoral injection of the AdmfVII/hIgG 1 Fc vector on the growth of a subcutaneous nodule derived from the MD MBA 435 human breast cancer cell line growing in nude mice. In this experiment, the tumor nodule which was followed for growth, was the same nodule subjected to intratumoral injection. We started injecting the tumor bearing mice with the AdmfVII/hIgG 1 Fc vector when the subcutaneous breast reached 50 mm 3 Mice with a dorsal skin fold chamber in which the N202 tumor spheroid (not carrying the histone 2B-GFP gene) was growing on a mammary fat pad explant were injected either with the mfVII-GFP protein (left hand panel) or first injected with the functional mfVII/hIgG 1 Fc protein and then injected 24 h later with the mfVII-GFP protein (right hand panel). One hour following the administration of the mfVII-GFP protein, the mice were killed. The tissue in the dorsal skin fold chamber was then harvested, impregnated with OCT freezing medium, and frozen in the vapor phase of dry ice. Frozen sections were fixed and then stained with FITC-conjugated antibody for PE-conjugated antibodies to the Tie-1 receptor. Similar experiments were carried out with PE-conjugated antibodies to the Tie-2 receptor, or to the a V b 3 integrin receptor. These sections of the tumor spheroid were photographed using the intravital microscope with a laser which was excitatory to the FITC or PE-reporter molecules and the two laser generated images superimposed to detect coincidence of binding of the factor VII-GFP protein and the PE-conjugated antibody. Yellow spots indicate coincident binding of the antibody to the mfVII-GFP molecule and the PE-conjugated antibody to the Tie-1 receptor on the tumor vascular endothelial cells. Mapping tumor vasculature for cancer treatment Y Tang et al nodules following a preceding injection of the mfVII/ hIgG 1 Fc vector, completely suppressed the growth of the subcutaneous tumor nodule as compared to an untreated control mouse (solid diamonds in Figure 5 ).
We then tested if the injection of the mfVII/hIgG 1 Fc vector into tissues other than the subcutaneous tumor nodule, such as the intramuscular injections (see the line defined by the open squares in Figure 5 ), subcutaneous injections (see the line defined by the solid circles in Figure 5 ) or intrahepatic injections (see line defined by the open circles in Figure 5 ), would suppress the growth of the uninjected subcutaneous tumor nodule derived from a breast cancer cell line. As shown by the results presented in Figure 5 , each of the non-intratumoral routes of the mfVII/hIgG 1 Fc vector injection (intramuscular, subcutaneous or intrahepatic injections) suppressed the growth of subcutaneous breast cancer nodules, when compared to the growth of mice not treated with injections of the mfVII/hIgG 1 Fc vector (see line defined by the solid diamonds in Figure 5 ). Using the t-test, the tumor growth rates in the mice receiving intratumoral injections of the AdmfVII/hIgG 1 Fc vector was statistically significantly slower than the growth of the tumor in the control animals at the P ¼ 0.04 level at 18 and 23 days. Again, the interval between successive tissue injections of the mfVII/ hIgG 1 Fc vector injections was timed to coincide with regrowth of the subcutaneous tumor nodule following an initial preceding tissue injection of the mfVII/hIgG 1 Fc.
These experiments showed that the mfVII/hIgG 1 Fc protein released into the blood from the vector-infected cells was effective in destroying not only the tumor vasculature but the tumor tissue as well. In addition, the use of the mfVII/hIgG 1 Fc vector for SC injections was as effective as the intravenous injections of the mfVII/ hIgG 1 Fc protein.
Discussion
Our results show that the vessels on the advancing or growing edge of the tumor spheroid express markers of vascular angiogenesis such as the Tie-2 receptor, the a V b 3 integrin receptor and tissue factor, whereas the vessels at the center of a tumor spheroid are negative for such markers. Hu and Garen [17] [18] [19] [20] showed that exposure to the mfVII/IgG 1 Fc can destroy tumor vessels as well as tumor cells and spares the normal vasculature. We showed that the destructive effect of the mfVII/hIgG 1 Fc protein to the tumor vasculature starts at 4 h resulting in a 50% reduction of the size of the tumor nodule by 24 h. The repetitive administration of the mfVII/hIgG 1 Fc induces tumor regression that reaches a plateau of 50% reduction over an 11-day period during which three injections are given at days 0, 3 and 7.
The partial response may be owing to the fact that the vessels located at the periphery or growing edge of the tumor spheroid are positive for tissue factor and other markers of angiogenesis (the Tie-2 receptor and the a V b 3 receptor), whereas these markers of angiogenesis are not detectable in the vascular endothelial cells at the center of a nodule of cancer cells (see Figure 1b) . Moreover, the fact that closely spaced multiple sequential exposures to the mfVII/hIgG 1 Fc treatment never reduces the size of the tumor nodules below 50% suggests that the vessels which are sensitive to the mfVII/IgG 1 Fc protein are destroyed following the initial exposure. This prediction was directly tested in the experimental results presented in Figure 4 . All of the angiogenic vascular markers were found to disappear following exposure of the tumor vasculature to the mfVII/hIgG 1 Fc.
Importantly however, when multiple sequential exposures to the mfVII/hIgG 1 Fc treatment are scheduled to coincide with regrowth of the tumor nodule following a partial response to a preceding exposure to the mfVII/ hIgG 1 Fc, continuous suppression of the growth of the tumor nodules derived from carcinomas of the breast and prostate can be achieved. These results suggest that tumor vascular targeting treatments for cancer, such as the mfVII/hIgG 1 FC protein or vector, should involve an initial exposure followed by re-exposure which coincides with regrowth of the tumor vasculature and tumor tissue. Hu and Garen [17] [18] [19] have reported previously that such an interval between exposures to the mfVII/hIgG 1 Fc protein may enhance the sensitivity of tumor vasculature to the suppressive effects of the mfVII/hIG 1 Fc, and led to durable complete regressions of subcutaneous tumor nodules in the human tumor xenograft model.
